Microbot Med Inc Stock Price, News & Analysis

Microbot Medical (Nasdaq: MBOT) has expanded its Scientific Advisory Board (SAB) with five renowned medical experts to enhance its leadership in micro-robotic technologies. The newly appointed members include specialists in interventional radiology and stroke therapy, such as Stephen B. Solomon, MD, and Ajay K. Wakhloo, MD PhD FAHA. CEO Harel Gadot emphasized the importance of attracting top talent to achieve significant clinical and regulatory milestones. Microbot Medical focuses on developing transformative technologies for minimally invasive procedures, contributing to advancements in the healthcare sector.

Microbot Medical (Nasdaq: MBOT) successfully completed an additional feasibility animal study of its LIBERTY™ Robotic System, achieving key study endpoints without any intraoperative adverse events. This study confirms LIBERTY's potential to enhance the safety and ease of conducting catheter-based neurovascular procedures remotely, minimizing risks associated with radiation exposure and contamination. CEO Harel Gadot expressed confidence in the system's performance and usability in clinical settings, with plans for further studies in the upcoming year to meet regulatory objectives.

Microbot Medical (Nasdaq: MBOT) has reported significant achievements for 2020, including the launch of the LIBERTY™ Robotic System, the first fully disposable surgical robotic system. Animal feasibility studies showed no adverse events, supporting remote catheter procedures to minimize physician risk. The company expanded its intellectual property with 40 patents granted. Leadership strengthened with new CMO and Board members, enhancing strategic capability. Looking ahead, Microbot aims to finalize FDA submissions for its technologies and continue exploring M&A opportunities in 2021.

Microbot Medical Inc. (Nasdaq: MBOT) announced that CEO Harel Gadot will present virtually at two investor conferences in January 2021. During the HCW Wainwright Bioconnect Conference, Mr. Gadot will engage in a fireside chat, with a video available on-demand from January 11-14. Additionally, he will present at the Needham Growth Conference on January 14 at 2:00 PM. Both presentations will be accessible via the Company’s website under the 'Investors' section. Microbot Medical focuses on micro-robotic technologies aimed at improving clinical outcomes for patients.

Microbot Medical (Nasdaq: MBOT) has announced the issuance of multiple patents, reinforcing its Intellectual Property (IP) portfolio, now comprising 40 issued/allowed patents and 23 pending applications globally. The USPTO granted a Notice of Allowance for its Self-Cleaning Shunt, enhancing its medical device technologies. Additionally, a European patent was granted for its guidewire technology under the LIBERTY development. CEO Harel Gadot emphasized the importance of a strong IP strategy to drive product development and future commercial opportunities.

Microbot Medical (Nasdaq: MBOT) will present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 2:00 PM ET. CEO Harel Gadot will discuss the company's recent progress and achievements. The event will also provide opportunities for virtual one-on-one meetings with executives for institutional investors. Gadot emphasizes the company's commitment to advancing its micro-robotic technologies toward commercialization. A live webcast will be available on the company's website for those interested.

Microbot Medical (Nasdaq: MBOT) received a Notice of Allowance for patent application No. 15/592,227 from the USPTO, enhancing its IP portfolio in devices for reducing dialysis shunt stenosis. This continuation of an existing patent reflects the company's commitment to protecting its innovative technologies. The newly allowed patent covers a system that reduces venous stenosis during hemodialysis, utilizing a novel clearing device. With a total of 39 issued/allowed patents and 23 pending applications globally, Microbot aims to solidify its competitive advantage in micro-robotic technologies.

Microbot Medical Inc. (NASDAQ: MBOT) will host a webinar on August 26, 2020, at 11:00 AM ET, following a successful presentation at the Needham Virtual Med Tech & Diagnostic Conference. CEO Harel Gadot will discuss the LIBERTY^TM Robotic System, which has achieved all endpoints in a recent feasibility animal study with no adverse events. The system's capabilities may enable catheter-based procedures to be performed remotely, enhancing clinical outcomes while minimizing risks like radiation exposure. Management will also address audience questions during the session.

Microbot Medical Inc. (Nasdaq: MBOT) will present initial results from a feasibility animal study of its LIBERTY Robotic System at the Needham Virtual Med Tech & Diagnostics Conference on August 17, 2020. The LIBERTY system is the first fully disposable robotic system designed to reduce radiation exposure for physicians. The company aims to innovate through its proprietary technologies, focusing on micro-robotic solutions within the human body. Further details will be available on their website prior to the conference.